Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9488312 | 0.87 | TRPV4 (0.41) | TRPV4CES2CES1KHKCYP11B1 | |
| SCHEMBL2234841 | 0.78 | TRPV4 (0.48) | TRPV4KHKCYP11B1CYP11B2DHODH | |
| SCHEMBL9491002 | 0.78 | TRPV4 (0.40) | TRPV4CES2CES1KHKCYP11B1 | |
| SCHEMBL31588414 | 0.77 | TRPV4 (0.48) | TRPV4CES2CES1KHKCYP11B1 | |
| SCHEMBL809090 | 0.77 | TRPV4 (0.48) | TRPV4CES2CES1KHKCYP11B1 | |
| SCHEMBL23850353 | 0.76 | AR (0.46) | TRPV4CES2CES1ARESR1 | |
| SCHEMBL20597951 | 0.76 | KHK (0.41) | TRPV4KHKCYP11B1CYP11B2DHODH | |
| SCHEMBL504867 | 0.76 | TRPV4 (0.39) | TRPV4CES2CES1KHKCYP11B1 | |
| SCHEMBL21455387 | 0.76 | TRPV4 (0.39) | TRPV4CYP11B1CYP11B2MAOAMAOB | |
| SCHEMBL20562679 | 0.76 | TSHR (0.38) | TRPV4CYP11B1CYP11B2DHODHAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| EP-0994849-B1 | METHOD FOR PRODUCTION OF 2,4,5-TRIFLUOROBENZONITRILE | BAYER AG (DE) | 2002-09-04 | — | — | EP | claimed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20250242338-A1 | IRON PHOSPHIDE NANOPARTICLES, AND COMPOSITE BODY AND REDUCTION CATALYST EACH CONTAINING SAME | OSAKA UNIVERSITY (JP) | 2025-07-31 | — | — | US | disclosed |
| EP-4509462-A1 | IRON PHOSPHIDE NANOPARTICLES, AND COMPOSITE BODY AND REDUCTION CATALYST EACH CONTAINING SAME | OSAKA UNIVERSITY (JP) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-119053551-A | Nano iron phosphide particles, composite containing nano iron phosphide particles and reduction catalyst | 国立大学法人大阪大学 | 2024-11-29 | — | — | CN | disclosed |
| US-12122768-B2 | Benzonitrile derivative, light-emitting material, and light-emitting element using same | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2024-10-22 | — | — | US | disclosed |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| CN-115135648-B | Dihydronaphthyridones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20030158179-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003028726-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
| US-6452056-B1 | REDUCING FLUORINATED BENZONITRILE TO A BENZYLAMINE WHICH IS REPLACED WITH A HYDROXYL GROUP | ASAHI GLASS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
| CN-1312783-A | Process for preparing fluorobenzyl derivatives | ASASHI GLASS CO (JP) | 2001-09-12 | — | — | CN | disclosed |
| EP-1114809-A1 | PROCESS FOR THE PREPARATION OF FLUOROBENZYL DERIVATIVES | Asahi Glass Co., Ltd. (JP) | 2001-07-11 | — | — | EP | disclosed |
| US-6075160-A | 4-cyano-2,5-difluoroaniline preparation process | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
| EP-0270964-B1 | PROCESS FOR OBTAINING SUBSTITUTED FLUOROBENZENES | BAYER AG (DE) | 1992-07-08 | — | — | EP | disclosed |
| US-4868347-A | SOLVENT EXTRACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122768-B2 | Benzonitrile derivative, light-emitting material, and light-emitting element using same | INTS9, GTF2I, BRI3BP | TRPV4 2087/4885CES2 1714/4885CES1 2870/4885 |
| US-20030158179-A1 | Quinoline derivatives | RAB1A, GLS, REN | TRPV4 3717/4885CES2 753/4885CES1 81/4885 |
| US-20250242338-A1 | IRON PHOSPHIDE NANOPARTICLES, AND COMPOSITE BODY AND REDUCTION CATALYST EACH CONTAINING SAME | FECH, PI4K2A, PHOSPHO1 | TRPV4 1443/4885CES2 3579/4885CES1 3141/4885 |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK4 | TRPV4 4569/4885CES2 4606/4885CES1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.